Pheochromocytoma Malignant: Clinical Trials

3 trials for Pheochromocytoma Malignant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 unknown. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 1, Recruiting 1, Unknown 1

Follow Pheochromocytoma Malignant: new trials by email Literature Review of Pheochromocytoma Malignant trials Research Report on Pheochromocytoma Malignant

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Experimental Study of Belzutifan Impact on Catecholamine Metabolism
Belzutifan - Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant
Phase 2RecruitingCambridge University Hospitals NHS Foundation Trust122026-04-272026-07-02
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Penpulimab - Pheochromocytoma, Metastatic, Pheochromocytoma Malignant
Phase 2UnknownPeking Union Medical College Hospital52023-04-012023-06-02
The Efficacy and Safety of Temozolomide in Patients With MPPGL
Temozolomide capsule - Pheochromocytoma, Metastatic, Paraganglioma, Malignant
Phase 2CompletedPeking Union Medical College Hospital622019-10-012023-05-15

Narrower conditions

Neoplasm Metastasis (3)  ·  Pheochromocytoma (3)  ·  Paraganglioma (2)  ·  Paraganglioma, Extra-Adrenal (2)

Broader conditions

Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms, Germ Cell and Embryonal (3)  ·  Neoplasms, Nerve Tissue (3)  ·  Neoplastic Processes (3)  ·  Neuroectodermal Tumors (3)  ·  Neuroendocrine Tumors (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Paraganglioma (1)

Interventions

Temozolomide (1)  ·  belzutifan (1)  ·  penpulimab (1)

Sponsors

Peking Union Medical College Hospital (2)  ·  Cambridge University Hospitals NHS Foundation Trust (1)

Countries

China (2)  ·  United Kingdom (1)

Top investigators

Anli Tong (2)  ·  Ruth T Casey, MD PhD (1)